Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Current Deferred Revenue (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Current Deferred Revenue for 7 consecutive years, with $9.1 million as the latest value for Q2 2025.

  • Quarterly Current Deferred Revenue fell 1.66% to $9.1 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Jun 2025, down 1.66% year-over-year, with the annual reading at $6.7 million for FY2024, 2.76% down from the prior year.
  • Current Deferred Revenue for Q2 2025 was $9.1 million at Strata Critical Medical, up from $8.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $10.0 million in Q2 2023, with the low at $4.4 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $7.1 million, with a median of $6.8 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue skyrocketed 61.41% in 2022, then fell 7.47% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $6.0 million in 2021, then increased by 12.27% to $6.7 million in 2022, then increased by 2.03% to $6.8 million in 2023, then decreased by 2.76% to $6.7 million in 2024, then skyrocketed by 36.9% to $9.1 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $9.1 million, $8.0 million, and $6.7 million for Q2 2025, Q1 2025, and Q4 2024 respectively.